ID | 1116 | |
PMID | 19709343 | |
Year | 2009 | |
Sequence | AETTNTQQAHTQMSTQ SQDVSYGTYYTIDSNG DYHHTPDGNWNQAMFD NKEYSYTFVDAQGHTH YFYNCYPKNANANGSG QTYVNPATAGDNNDYT ASQSQQHINQYGYQSN VGPDASYYSHSNNNQAY NSHDGNGKVNYPNGTS NQNGGSASKATASGHA KDASWLTSRKQLQPYG QYHGGGAHYGVDYAMP ENSPVYSLTDGTVVQA GWSNYGGGNQVTIKEA NSNNYQWYMHNNRL | |
Name | Lysostaphin | |
Length | 291 | |
N-Terminal Modification | Free | |
C-Terminal Modification | Free | |
Linear/ Cyclic | Linear | |
Chirality | L | |
Chemical Modification | None | |
Origin of Peptide | Staphylococcus simulans | |
Nature of Peptide/Cargo | Endopeptidase,Antimicrobial | |
Mechanism | It is a glycylglycine endopeptidase, an antibacterial enzyme which is capable of cleaving the crosslinking pentaglycin bridges in the cell wall of Staphylococci | |
Cargo Sequence/Structure | None | |
Name of cargo | Not applicable | |
Assay | Franz diffusion cell | |
Enhancer | None | |
Properties of enhancer | Not applicable | |
Concentration | 10 µl MRSA252 suspension (1·108 CFU ml-1) which was allowed to dry at 25°C; 30 min, 50µl of a treatment solution made up in PBS (1 mg -1l) lysostaphin | |
Incubation time | 30 minutes | |
Tissue permeability (value with units) | Lysostaphin (1 mg l-1) caused a 1.95 ± 0.23 log10 CFU reduction in bacteria | |
Tissue Sample | Abdominal skin from a 38-year-old white female donor | |
Ex vivo/In vivo/In vitro | ex vivo | |
STRUCTURE |
| |
SMILES | N.A. |